ArticleThe Journal of antimicrobial chemotherapy2024

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.

Heather I Henderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.